Polyclonal Antibodies Market Size & Share 2023 to 2032

Polyclonal Antibodies Market Size

Polyclonal Antibodies Market size was valued more than USD 1.5 Billion in 2022 and is projected to grow at a CAGR of over 5.9% between 2023 and 2032. The rising incidence of chronic diseases such as cancer, autoimmune conditions, and infectious diseases anticipates propelling the industry demand. For instance, there were around 20 million new cancer cases, and the cancer burden is projected to rise by about 60% in the next two decades, reaching approximately 30 million new cases by 2040. This surge in cancer cases is expected to drive the demand for diagnostics and therapeutics.

Polyclonal antibodies are a group of antibodies that are produced by different B cells in the immune system. These antibodies are diverse and can recognize and bind to various epitopes (specific regions on an antigen) due to their origins from multiple B cell clones. Due to their broad epitope recognition, polyclonal antibodies are valuable tools in various applications, including diagnostics, therapeutics, and research.
 

COVID-19 Impact

The polyclonal antibodies industry experienced a substantial surge in 2020. Collaborative efforts involving pharmaceutical companies, research institutions, and governments played a pivotal role in expediting the manufacturing and distribution of polyclonal antibodies.. For instance, in a publication in the International Pathogens journal, GigaGen Inc. unveiled a peer-reviewed study detailing a recombinant polyclonal product engineered to combat SARS-CoV-2.
 

Polyclonal Antibodies Market Trends

• The market is driven by several key factors that collectively contribute to its gains and prominence in the biomedical and pharmaceutical industries. Rising prevalence of chronic diseases, including cancer, autoimmune disorders, and infectious diseases, acts as a significant driver. As the global burden of these diseases rises, the demand for versatile and effective tools for diagnosis and treatment, such as polyclonal antibodies.
   
• For instance, over 80 autoimmune diseases, including type 1 diabetes, multiple sclerosis, and rheumatoid arthritis, impact nearly 4% of the global population. In the U.S. alone, autoimmune diseases rank as the third most prevalent cause of chronic illness, affecting 5-8% of the population, according to the National Institute of Health (NIH).
   
• Moreover, research collaboration and fundings contribute to expand the polyclonal antibodies industry. For instance, in October 2022, SAB Biotherapeutics has secured an exclusive manufacturing services agreement with Emergent BioSolutions Inc. Within this partnership, Emergent will offer contract development and manufacturing (CDMO) services for the SAB's fully human polyclonal antibody production/products. This collaboration enables SAB to concentrate exclusively on the research and development of their polyclonal antibodies.
   

Polyclonal Antibodies Market Analysis

Based on product, the market is segmented into primary antibodies and secondary antibodies. The secondary antibodies segment held the largest industry share at 66.4% in 2022.
 

• The dominance of secondary antibodies in the industry can be attributed to their role in signal amplification during detection methods like ELISA, western blotting and immunohistochemistry.
   
• Further, the ability to recognize multiple epitopes on antibodies enable to enhance assay sensitivity and specificity. Similarly, the flexibility and signal amplification capability remark the secondary antibodies as a preferred choice.
   

Learn more about the key segments shaping this market

Download Free PDF

Based on application, the polyclonal antibodies market is classified into diagnostics, therapeutics, and research. The diagnostics segment is expected to mark its dominance in 2022 accounting for the highest share of 59%.
 

• The extensive use of polyclonal antibodies in diagnostic assays, such as ELISA, immunohistochemistry, and western blotting, has driven their dominance. The antibodies detect numerous epitopes on target antigens as well as the unknow antigens due to its enhanced sensitivity and specificity that makes it suitable for diagnostic tests.
   
• Further, with a rising demand for accurate disease detection and monitoring, polyclonal antibodies play a pivotal role in various diagnostic applications.
   

Based on route of administration, the polyclonal antibodies market is classified into intravenous (IV), subcutaneous (SC), and other routes of administration. The intravenous (IV) segment is expected to exhibit CAGR of 5.3% by 2032.
 

• The popularity of intravenous administration in clinical settings, along with its convenience and established safety profile, consolidates its dominance in the market Intravenous (IV), route is preferred for several polyclonal antibody-based treatments as it allows precise dosing control and immediate systemic distribution. According to a study published in NCBI, approximately 70% of the antibodies are administered via intravenous (IV) injection, enabling rapid systemic drug delivery. And maximizing their bioavailability.
   

Based on source, the market is categorized into rabbit, goat, mouse, human and other sources. In 2022, the rabbit segment accounted for USD 826.9 million revenue.
 

• Rabbit polyclonal antibodies have been found in widespread application in biomedical research, particularly in immunological techniques like immunohistochemistry, western blotting, and flow cytometry.
   
• The preference for rabbit polyclonal antibodies was attributed due to its rapid immune response against small molecules, and post-translational modifications.
   
• These antibodies exhibit superior affinity and specificity compared to other sources, demonstrating high binding capability in the picomolar range.
   

Based on end-users, the global polyclonal antibodies market is categorized into pharmaceutical & biotechnology companies, academic and research institutes, contract research Organizations (CROs), diagnostic laboratories and other end-users. The pharmaceutical & biotechnology companies segment led the industry share with a 45.9% in 2022.
 

• Pharmaceutical & biotechnology companies are at the forefront of the industry, driven by heightened demand for these antibodies in drug discovery, development, and increased investment in biologics.
   
• Also, companies are actively collaborating with other companies and end-users to improve their R&D capabilities extending pipeline studies, investing in research to create effective products that meet therapeutic requirements.
   

In 2022, North America held a significant market share of 38.3% in the polyclonal antibodies market.
 

• North America establishes its dominance in the industry due to a confluence of factors. The region's advanced healthcare infrastructure, substantial research & development activities, and robust biotechnology industry.
   
• Moreover, the presence of key market players, strategic collaborations between academic institutions and pharmaceutical companies, and increasing investments in biomedical research further propel the business progression.
   

Polyclonal Antibodies Market Share

The polyclonal antibodies industry is characterized by the presence of leading key players such as Thermo Fisher Scientific, Abcam plc, and Bio-Rad Laboratories. These companies engage in strategic initiatives, including product launches, collaborations, and acquisitions, to strengthen their market positions.
 

Prominent market players operating in the industry is as mentioned below:

• Thermo Fisher Scientific Inc.
• F. Hoffmann-La Roche Ltd.
• Merck Group (Merck KGaA)
• Abcam plc
• Bio-Rad Laboratories, Inc.
• GenScript Biotech Corporation
• Cell Signaling Technology, Inc.
• Rockland Immunochemicals Inc.
• BioLegend, Inc.
• Santa Cruz Biotechnology, Inc.
• Antibodies Inc.
• Emergent
   

Polyclonal Antibodies Industry News:

• In April 2022, Aviva Systems Biology announced its new service namely high-throughput services for antibody characterization by utilizing the cutting-edge Carterra LSATM platform. This service offers small to mid-size biotechs' drug development researchers an economical and convenient option for quick therapeutic antibody screening, kinetic analysis, and epitope mapping and binning. This strategy enabled company to enhance its service offerings, thereby strengthening its market position.
   
• In December 2021, Atlas Antibodies launched 1,200 novel Triple-A Polyclonals. With this launch, the company offer over 22,000 highly validated primary antibodies for tissue and cell analysis. This strategy enabled company to add value to its existing business portfolio.
   

The polyclonal antibodies market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2018 to 2032 for the following segments:

Click here to Buy Section of this Report

By Product, 2018 – 2032 (USD Million)

• Primary antibodies
• Secondary antibodies

By Application, 2018 – 2032 (USD Million)

• Diagnostics
• Therapeutics
• Research

By Route of Administration, 2018 – 2032 (USD Million)

• Intravenous (IV)
• Subcutaneous (SC)
• Other routes of administration

By Source, 2018 – 2032 (USD Million)

• Rabbit Polyclonal Antibodies
• Goat Polyclonal Antibodies
• Mouse Polyclonal Antibodies
• Human
• Other sources

By End-user, 2018 – 2032 (USD Million)

• Pharmaceutical and Biotechnology Companies
• Academic and Research Institutes
• Contract Research Organizations (CROs)
• Diagnostic Laboratories
• Other end-users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada 
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • Rest of Middle East & Africa